Combining Dapagliflozin and Sildenafil for Heart Failure with Pulmonary Hypertension
The Effect of Combination of Dapagliflozin and Sildenafil in Treatment of Heart Failure Patients with Secondary Pulmonary Hypertension
This study is testing if adding sildenafil to dapagliflozin can help people with heart failure and pulmonary hypertension feel better and improve their heart function.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Fayoum University Academic / other |
| Locations | 1 site (Fayoum) |
| Trial ID | NCT06778330 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of sildenafil as an additional treatment to dapagliflozin in patients suffering from heart failure with secondary pulmonary hypertension. It aims to compare the outcomes of this combination therapy against the use of dapagliflozin alone. The study will enroll patients diagnosed with heart failure who experience symptoms such as dizziness, heart palpitations, and shortness of breath. The goal is to determine if the combination therapy can provide better relief from symptoms and improve overall heart function.
Who should consider this trial
Good fit: Ideal candidates are adults with established heart failure and secondary pulmonary hypertension who experience specific symptoms related to their condition.
Not a fit: Patients with contraindications to sildenafil or dapagliflozin, or those with pulmonary arterial hypertension from other causes, will not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment approach could significantly improve the management of heart failure patients with secondary pulmonary hypertension.
How similar studies have performed: While the combination of these medications has not been extensively tested together, similar studies have shown promise in treating related conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: patients with established heart failure with secondary pulmonary hypertension seen by a primary care provider to diagnose a heart disease, the patient's symptoms which may experience: * Dizziness or fainting * Heart palpitations, which may feel like your heart fluttering or skipping beats * Shortness of breath Exclusion Criteria: * Patients with a history of severe allergic reactions or hypersensitivity to sildenafil, dapagliflozin, or related medications. * Individuals with contraindications to the use of sildenafil or dapagliflozin. * Patients with pulmonary arterial hypertension (PAH) due to conditions other than heart failure (e.g., idiopathic PAH). * severe hepatic impairment * aged less than 18 years. * valvular heart disease . * Patients with a known or suspected history of non-compliance with medical treatment or inability to adhere to study procedures. * life expectancy of less than 6 months . * Pregnant or breastfeeding women
Where this trial is running
Fayoum
- Fayoum University — Fayoum, Egypt (Recruiting)
Study contacts
- Study coordinator: esraa mohamed abdallah, teaching assistant
- Email: ema17@fayoum.edu.eg
- Phone: 01019976442
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.